XML 42 R35.htm IDEA: XBRL DOCUMENT v3.25.2
Collaboration Agreements, License Agreement and Revenues - Astellas Agreements - Additional Information (Detail) - USD ($)
 1 Months Ended 3 Months Ended 6 Months Ended
Apr. 30, 2006
Jun. 30, 2005
Jun. 30, 2025
Jun. 30, 2024
Jun. 30, 2025
Jun. 30, 2024
Dec. 31, 2024
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]              
Total revenue     $ 1,348,000 $ 998,000 $ 4,088,000 $ 26,363,000  
Deferred Revenue     27,311,000   27,311,000   $ 27,290,000
Drug Product Revenue, Net [Member]              
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]              
Total revenue     1,215,000 729,000 3,811,000 25,216,000  
Japan [Member]              
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]              
Transaction price, variable consideration from estimated future co-development billing         0    
Europe [Member]              
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]              
Transaction price, variable consideration from estimated future co-development billing         $ 0    
Astellas Agreement [Member] | Japan [Member]              
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]              
Upfront, non-contingent and time-based payments received   $ 172,600,000          
Additional consideration based on net sales description         the low 20% range of the list price    
Aggregate consideration received excluding drug product revenue     105,100,000   $ 105,100,000    
Transaction price, variable consideration from estimated future co-development billing     0 0 0 0  
Changes in revenue from changes to estimated variable consideration         0    
Astellas Agreement [Member] | Japan [Member] | License [Member]              
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]              
Cash Consideration Received Under Collaboration Agreement     100,300,000   100,300,000    
Astellas Agreement [Member] | Japan [Member] | Co-development, information sharing & committee services [Member]              
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]              
Cash Consideration Received Under Collaboration Agreement     17,100,000   $ 17,100,000    
Astellas Agreement [Member] | Europe [Member]              
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]              
Upfront, non-contingent and time-based payments received $ 745,000,000            
Additional consideration based on net sales description         low 20% range    
Aggregate consideration received excluding drug product revenue     685,000,000   $ 685,000,000    
Percentage of joint development costs committed to fund 50.00%            
Changes in revenue from changes to estimated variable consideration     0        
Astellas Agreement [Member] | Europe [Member] | License [Member]              
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]              
Total revenue     0 $ 0 0 $ 0  
Cash Consideration Received Under Collaboration Agreement     619,000,000   619,000,000    
Astellas Agreement [Member] | Europe [Member] | Co-development, information sharing & committee services [Member]              
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]              
Cash Consideration Received Under Collaboration Agreement     $ 288,400,000   $ 288,400,000